Randomized Trialhigh evidence
Asundexian for Secondary Stroke Prevention.
The New England journal of medicine·April 16, 2026·PMID 41985132
Why it mattersCurrent secondary stroke prevention relies on antiplatelet agents, which carry bleeding risk. Asundexian offers a novel mechanism targeting factor XIa, potentially uncoupling thrombosis from hemostasis, and this large trial demonstrates efficacy without excess major bleeding.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled